Table 2.
Clinicopathological features of main pancreatic duct (MPD)-involved type intraductal papillary mucinous neoplasms (IPMNs)
| Total (n = 88) | Low-intermediate grade (n = 47) | High-grade/invasive carcinoma (n = 41) | p | |
|---|---|---|---|---|
| Age (years) | 64.52 ± 8.83 | 64.94 ± 8.29 | 64.05 ± 9.48 | 0.641 |
| Size (cm) | 3.88 ± 1.94 | 3.95 ± 2.09 | 3.79 ± 1.75 | 0.702 |
| Sex (male/female) | 55/33 | 27/20 | 28/13 | 0.294 |
| Location | ||||
| Head and neck | 61 (69.32%) | 28 (59.57%) | 33 (80.49%) | 0.046 |
| Body and tail | 26 (30.68%) | 18 (40.43%) | 8 (19.51%) | |
| CEA (ng/ml) | 4.08 ± 4.46 | 3.24 ± 2.22 | 5.03 ± 5.99 | 0.060 |
| CA19-9 (U/ml) | 66.93 ± 299.17 | 16.04 ± 25.78 | 126.74 ± 435.65 | 0.085 |
| MPD diameter (mm) | 9.03 ± 4.33 | 8.15 ± 4.29 | 10.01 ± 4.22 | 0.045 |
| Mural nodule (yes) | 14 (15.91%) | 4 (8.51%) | 10 (24.39%) | 0.042 |
| Lymph node metastasis (yes) | 2 (2.27%) | 0 | 2 (4.88%) | 0.214 |
| Extra-pancreas extension (yes) | 5 (5.68%) | 0 | 5 (12.20%) | 0.019 |
| Symptom (yes) | 38 (43.18%) | 17 (36.17%) | 21 (52.22%) | 0.155 |
| Pancreatitis (yes) | 0 | 0 | 0 | – |
| Diabetes Mellitus (yes) | 17 (17.29%) | 4 (8.51%) | 13 (31.70%) | 0.006 |
| Complications (yes) | 37 (42.05%) | 20 (42.55%) | 17 (41.46%) | 0.918 |
CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen